中关村(000931.SZ)：盐酸丁螺环酮片一致性评价申报收到《受理通知书》

Core Viewpoint - Zhongguancun (000931.SZ) announced that its subsidiary, Beijing Huasu Pharmaceutical Co., Ltd., has received an acceptance notice from the National Medical Products Administration for the consistency evaluation application of the generic drug, Buprenorphine Hydrochloride Tablets [1] Group 1 - The drug Buprenorphine is the first non-benzodiazepine anxiolytic, acting as a 5-HT1A receptor agonist [1] - It selectively binds to the brain's 5-HT1A receptors, reducing excessive 5-HT activity associated with anxiety disorders [1] - The clinical advantage of this drug is its lack of dependency and withdrawal reactions, indicating a higher safety profile [1]